Pediatric focus Target opportunities in pediatric hypertension and heart failure management, leveraging Silvergate’s EPANED oral solution and emphasis on safe, accurate dosing for children.

Acquisition history Note that the company was acquired by CutisPharma in 2019; potential for channel expansion through the acquirer’s distribution network and legacy products.

Regulatory edge Highlight first‑to‑market FDA‑approved pediatric enalapril formulation; pursue partnerships with hospitals and compounding centers seeking approved pediatric ACE inhibitors with reliable dosing.

Growth potential With a small team and revenue in the low millions, there is room to partner on additional pediatric formulations or line extensions that complement Epaned and existing SafeMed dosing platforms.

Funding leverage Explore co‑development or milestone-based deals financed by the company’s $26M funding and moderate revenue upside to de‑risk joint ventures in pediatric cardiovascular therapies.